Author: Healio ophthalmology

Speaker: Gene therapy well-suited for retinal disease treatment

LAS VEGAS — Safety results in the phase 2a trial of AVA-101 support ocular gene therapy as a potential long-term treatment option for wet age-related macular degeneration, according to a presentation here. There is, however, still a need for anti-VEGF rescue therapy. Jeffrey S. Heier, MD, related topline results from the phase 1 and 2a clinical trials of AVA-101 (Avalanche Biotechnologies) at Retina Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.

Mynosys focuses on bringing automated capsulotomy device to market

LAS VEGAS — Zepto is an “innovative disposable device” that utilizes “precision pulsed technology” to create capsulotomies and shows promise in adoption by cataract surgeons when it comes to market, according to the company’s senior executive.John Hendrick, president and CEO of Mynosys Cellular Devices, told colleagues at the Ophthalmology Innovation Summit here that “for many months and years,” the company has been focusing on being able to create “a perfectly round capsulotomy, every time.”

Speaker calls for prospective studies of donor diabetes and keratoplasty outcomes

LAS VEGAS — Because the effect of donor diabetes history on keratoplasty outcomes is unknown, there is a need for prospective studies to manage its impact, according to a presentation here. Jonathan Lass, MD, discussed the growing problem of the impact of donor diabetes on the future of the cornea donor pool and patients requiring keratoplasty at the American Academy of Ophthalmology annual meeting.

Contact lens wearers at greater risk for Acanthamoeba keratitis than non-lens wearers

LAS VEGAS — In patients who are diagnosed with Acanthamoeba keratitis, 85% to 100% are contact lens wearers and 33% are orthokeratology patients, according to a speaker here. “The rates of risk are the same or very similar for hard and soft contact lens wearers. Orthokeratology patients are especially high risk… luckily, if you are a noncontact lens wearer, the risk is fairly low,” Elmer Y. Tu, MD, said at Cornea Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.

OASIS: Single Jetrea injection results in long-term resolution of vitreomacular adhesion

LAS VEGAS — A single intravitreal injection of 0.125 mg of ocriplasmin can result in long-term resolution of vitreomacular adhesion, according to a presentation here. At the American Academy of Ophthalmology annual meeting, Peter K. Kaiser, MD, presented results from the OASIS study evaluating a single injection of Jetrea (ocriplasmin, Thrombogenics) in patients with vitreomacular adhesion (VMA), including macular hole, and vitreomacular traction (VMT) at 24 months.

Speaker: Prevention key to managing neurotrophic keratopathy

LAS VEGAS — Prevention is key to managing varicella zoster virus neurotrophic keratopathy, according to a speaker here. “This is the diabetic foot ulcer of the eye,” Todd Margolis, MD, PhD, said at Cornea Subspecialty Day preceding the American Academy of Ophthalmology meeting. Neurotrophic keratopathy is characterized by decreased corneal sensation and poor corneal healing.

Early BCVA response may predict long-term outcomes of anti-VEGF treatment for DME

LAS VEGAS — Best corrected visual acuity response after three anti-VEGF injections for 12 weeks may be a strong predictor of long-term best corrected visual acuity response in patients with diabetic macular edema patients, according to a presentation here.In an assessment of Protocol I data from the DRCR.net, Pravin U. Dugel, MD, presented long-term treatment outcomes of anti-VEGF therapy in patients with diabetic macular edema at the American Academy of Ophthalmology annual meeting.

Oral acyclovir may be used to prevent recurrence of herpes simplex keratitis

LAS VEGAS — Recurrence of herpes simplex keratitis is commonly associated with corneal scarring and poor corneal graft survival. Early diagnosis and treatment helps prevent permanent corneal scarring caused by the virus’ lytic reaction and its immune-mediated response, according to a speaker here. Daily applications of trifluridine 1% solution or ganciclovir 0.15% are commonly used to treat acute herpetic epithelial keratitis and have been shown to shorten the clinical course, Natalie Afshari, MD, said here at Cornea Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.